DavidLPorterMD

PubMed

• Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
  Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Ma...> ;Haematologica. 2024 Apr 18
• Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
  Elise A Chong, Emeline R Chong, Dylan Therwhangher, Sunita D Nasta, Daniel J Landsburg, Stefan K Barta, Jakub Svoboda, James N Gerson, Guido Ghilardi, Luca Paruzzo, Jo...> ;Transplantation and Cellular Therapy. 2024 Mar 16
• 1 citations
  The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma.
  Lucy Andersen, Kayla M Baker, Heather Difilippo, Salimah H Meghani, David Porter, Jie Deng> ;Seminars in Oncology Nursing. 2024 Mar 4
• A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help.
  Kevin J Curran, Sarah Nikiforow, Carlos Bachier, Yen-Michael Hsu, Marcela V Maus, Basem William, Kara Wacker, Phyllis Warkentin, Helen E Heslop, David Maloney, Philip ...> ;Blood Advances. 2024 Feb 27
• 1 citations
  Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
  Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E., Shestov, A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S., Porazzi, P., Landsburg, D., Gerson, J., Carter, J., Bart...> ;Blood Advances. 2024 Feb 13
• Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
  Anthony D Sung, Thuy Koll, Shannon H Gier, Alessandro Racioppi, Griffin White, Meagan Lew, Marcia Free, Priyal Agarwal, Lauren M Bohannon, Ernaya J Johnson, Bharathi S...> ;Transplantation and Cellular Therapy. 2024 Apr 1
• 5 citations
  Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
  Levine, B., Pasquini, M., Connolly, J., Porter, D., Gustafson, M., Boelens, J., Horwitz, E., Grupp, S., Maus, M., Locke, F., Ciceri, F., Ruggeri, A., Snowden, J., Hesl...> ;Nature Medicine. 2024 Feb 1
• 3 citations
  Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
  Michael Scordo, Jessica R Flynn, Mithat Gonen, Sean M Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L Porter, Stephen J Schuster, ...> ;Blood Advances. 2023 Sep 26
• 11 citations
  Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
  Sangya Agarwal, M Angela Aznar, Andrew J Rech, Charly R Good, Shunichiro Kuramitsu, Tong Da, Mercy Gohil, Linhui Chen, Seok-Jae Albert Hong, Pranali Ravikumar, Austin ...> ;Immunity. 2023 Oct 10
• 3 citations
  Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
  Shakthi T Bhaskar, David L Porter, Stephen J Schuster, Loretta J Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R Bishop, Joseph P McGuirk, Richard T Mazi...> ;Blood Advances. 2023 Sep 12
• One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.
  Lindsey Chippendale, Craig W Freyer, Alison Carulli, Daria V Babushok, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Selina M Luger, Mary Ellen Martin, David L Porte...> ;Journal of Oncology Pharmacy Practice. 2023 Aug 21
• The Cell and Gene Therapy Consortium's Perspective on Harmonizing Data Collection for Patient Enrollment, Therapy Ordering and Scheduling, and Cell Collection.
  Alexandra Mora, Linda Barnes, Clint Divine, Noelle Frey, Christian Fuchs, Beth Hayes, Dawn Henke, Peter Holman, Hien Liu, David Porter, Kirstin Powel, Sanjay Srivastava> ;Transplantation and Cellular Therapy. 2023 Nov 1
• 9 citations
  Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
  Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, Sean M Devlin, Jamie Brower, Veronika Bachanova, Loretta J Nastoupil, Joseph P McGuirk, Richard T Maziarz, Olale...> ;Blood Advances. 2023 Jul 11
• 2 citations
  Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
  Mushtaq, M., Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L Porter, Sunita D Nasta, Jamie Brower, Veronika Bachanova, Marie Hu, Loretta J Nastoupil, O...> ;Transplantation and Cellular Therapy. 2023 Jul 1
• 3 citations
  Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
  Andrew H Matthews, Alexander E Perl, Selina M Luger, Saar I Gill, Catherine Lai, David L Porter, Sarah Skuli, Ximena Jordan Bruno, Martin P Carroll, Craig W Freyer, Al...> ;American Journal of Hematology. 2023 Aug 1
• 1 citations
  Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or...
  Daniel J Landsburg, Sunita D Nasta, Jakub Svoboda, James N Gerson, Stephen J Schuster, Stefan K Barta, Elise A Chong, Heather Difilippo, Elizabeth Weber, Kathleen Cunn...> ;Transplantation and Cellular Therapy. 2023 Aug 1
• 9 citations
  Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
  Mireia Uribe-Herranz, Silvia Beghi, Marco Ruella, Kalpana Parvathaneni, Silvano Salaris, Nektarios Kostopoulos, Subin S George, Stefano Pierini, Elisavet Krimitza, Fra...> ;Molecular Therapy. 2023 Mar 1
• 36 citations
  Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
  Saar Gill, Vanessa Vides, Noelle V Frey, Elizabeth O Hexner, Susan Metzger, Megan O'Brien, Wei-Ting Hwang, Jennifer L Brogdon, Megan M Davis, Joseph A Fraietta, Avery ...> ;Blood Advances. 2022 Nov 8
• 1 citations
  Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
  Matthew P Connor, Alison W Loren, Elizabeth O Hexner, Mary Ellen Martin, Saar I Gill, Selina M Luger, James K Mangan, Alexander E Perl, Shannon R McCurdy, Keith W Prat...> ;Transplantation and Cellular Therapy. 2023 Feb 1
• 32 citations
  Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Ce...
  Riedell, P., Hwang, W., Nastoupil, L., Pennisi, M., McGuirk, J., Maziarz, R., Bachanova, V., Oluwole, O., Brower, J., Flores, O., Ahmed, N., Schachter, L., Bharucha, K...> ;Transplantation and Cellular Therapy. 2022 Oct 1
• 4 citations
  Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
  Craig W Freyer, Daria V Babushok, Noelle V Frey, Saar I Gill, Alison W Loren, Selina M Luger, Amit Maity, Mary Ellen Martin, John P Plastaras, David L Porter, Elizabet...> ;Transplantation and Cellular Therapy. 2022 Sep 1
• 3 citations
  Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.
  Yimei Li, Wei-Ting Hwang, Shannon L Maude, David T Teachey, Noelle V Frey, Regina M Myers, Allison Barz Leahy, Hongyan Liu, David L Porter, Stephan A Grupp, Pamela A Shaw> ;Clinical Cancer Research. 2022 Sep 15
• 33 citations
  Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
  Andrew H Matthews, Alexander E Perl, Selina M Luger, Alison W Loren, Saar I Gill, David L Porter, Daria V Babushok, Ivan P Maillard, Martin P Carroll, Noelle V Frey, E...> ;Blood Advances. 2022 Jul 12
• 1 citations
  Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease.
  Craig W Freyer, Shannon Gier, Alison Carulli, Saar I Gill, Elizabeth O Hexner, Alison W Loren, Mary Ellen Martin, David L Porter> ;American Journal of Hematology. 2022 Jul 1
• Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
  Rachel V Hatch, Craig W Freyer, Alison Carulli, Gretchen Redline, Daria V Babushok, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Selina M Luger, Mary Ellen Martin, ...> ;Journal of Oncology Pharmacy Practice. 2022 Jun 1
• Join now to see all

Journal Articles

• Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients  
  Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases
• Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells  
  Shannon A Carty, Carl H June, David L Porter, Bruce L Levine, Rahul M Kohli, Nature
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018